Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
暂无分享,去创建一个
C K Osborne | G M Clark | C. Osborne | D. Allred | G. Clark | C. Osborne | J. Harvey | D C Allred | J M Harvey
[1] T. Grogan,et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[3] M. Untch,et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Morey,et al. SUGGESTIONS FOR HER‐2/neu TESTING IN BREAST CARCINOMA, BASED ON A COMPARISON OF IMMUNOHISTOCHEMISTRY AND FLUORESCENCE IN SITU HYBRIDISATION , 2001, Pathology.
[5] A. Thor. HER2--a discussion of testing approaches in the USA. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] D. Slamon,et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Simon,et al. Comparative methodological analysis of erbB‐2/HER‐2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use , 2000, Histopathology.
[8] A. Vincent-Salomon,et al. Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma , 2000, Modern Pathology.
[9] N. Sneige,et al. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. , 2000, American journal of clinical pathology.
[10] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[11] D. Barnes,et al. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. , 1996, British Journal of Cancer.
[12] J. Feldman,et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Spγ in frozen sections or cytosol‐based ligand‐binding assays , 1996, Cancer.
[13] L. Layfield,et al. Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early‐stage breast carcinomas: Prognostic significance , 1996, Journal of surgical oncology.
[14] G. Clark,et al. Practical p-value adjustment for optimally selected cutpoints. , 1996, Statistics in medicine.
[15] M. Fernö,et al. Oestrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome after adjuvant tamoxifen treatment. The South Sweden Breast Cancer Group. , 1996, Acta oncologica.
[16] A. Ramos,et al. Immunohistochemical correlation of steroid receptors and disease-free interval in 206 consecutive cases of breast cancer: validation of telequantification based on global scene segmentation. , 1995, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.
[17] R W Blamey,et al. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. , 1995, Human pathology.
[18] J M Esteban,et al. Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer. , 1994, American journal of clinical pathology.
[19] W. Sauerbrei,et al. Steroid receptors in carcinoma of the breast. Results of immunocytochemical and biochemical determination and their effects on short-term prognosis. , 1994, Analytical and quantitative cytology and histology.
[20] W. Weikel,et al. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC). , 1994, Gynecologic Oncology.
[21] W. Hanna,et al. The predictive value of ERICA in breast cancer recurrence. A univariate and multivariate analysis. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[22] S. Gebhard,et al. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas , 1993, Histopathology.
[23] W. McGuire,et al. Immunohistochemistry on Histological Sections from Small (50 mg) Samples of Pulverized Breast Cancer , 1993 .
[24] W. McGuire,et al. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer , 1993, Cancer.
[25] W. McGuire,et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.
[26] M. Indelli,et al. Clinical Usefulness of Estrogen Receptor Immunocytochemistry in Human Breast Cancer , 1992, Tumori.
[27] R. Blamey,et al. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. , 1992, British Journal of Cancer.
[28] W. L. McGuire,et al. Breast cancer prognostic factors: evaluation guidelines. , 1991, Journal of the National Cancer Institute.
[29] B. Rasmussen,et al. Estrogen receptor in primary breast cancer estimated in paraffin-embedded tissue. A study of its usefulness compared to dextran-coated charcoal assay. , 1991, Acta oncologica.
[30] M. Schemper,et al. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. , 1990, Cancer research.
[31] G. Greene,et al. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival , 1990, Cancer.
[32] B. Reid,et al. Oestrogen receptor in breast cancer: prognostic studies using a new immunohistochemical assay , 1990, Histopathology.
[33] D Nicholson,et al. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. , 1990, Cancer research.
[34] I. Christensen,et al. The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays. , 1990, European journal of cancer.
[35] D. Allred,et al. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. , 1990, Archives of surgery.
[36] R. J. Sklarew,et al. Quantitative imaging of immunocytochemical (PAP) estrogen receptor staining patterns in breast cancer sections. , 1990, Cytometry.
[37] H. Poulsen,et al. Immunohistochemical estrogen receptor determination in paraffin‐embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer , 1989, Cancer.
[38] R. Hawkins,et al. RELATION BETWEEN IMMUNOCYTOCHEMICAL ESTIMATION OF OESTROGEN RECEPTOR IN ELDERLY PATIENTS WITH PRIMARY BREAST CANCER AND RESPONSE TO TAMOXIFEN , 1989, The Lancet.
[39] G M Clark,et al. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. , 1989, The New England journal of medicine.
[40] E. Szabo,et al. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. , 1989, Cancer research.
[41] I. Ellis,et al. Immunocytochemical localization of estrogen receptor in human breast tissue. , 1988, Cancer research.
[42] U. Chetty,et al. The cytochemical detection of oestrogen receptors in fine needle aspirates of breast cancer; correlation with biochemical assay and prediction of response to endocrine therapy. , 1988, British Journal of Cancer.
[43] A. Paradiso,et al. Correlation between ERICA and DCC assay in hormone receptor assessment of human breast cancer. , 1988, Oncology.
[44] H. Poulsen,et al. Immunohistochemical analysis of estrogen receptors (ER) using formalin-fixed paraffin-embedded breast cancer tissue: correlation with clinical endocrine response. , 1988, Journal of steroid biochemistry.
[45] R. Coombes,et al. Detection of estrogen receptor in bone marrow from patients with metastatic breast cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] T. Powles,et al. PREDICTION OF ENDOCRINE RESPONSE IN BREAST CANCER BY IMMUNOCYTOCHEMICAL DETECTION OF OESTROGEN RECEPTOR IN FINE-NEEDLE ASPIRATES , 1987, The Lancet.
[47] B. Rasmussen,et al. Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. , 1986, Cancer research.
[48] W. Jonat,et al. Immunohistochemical measurement of estrogen receptors in breast cancer tissue samples. , 1986, Cancer research.
[49] T. Powles,et al. Immunocytochemical assay for estrogen receptor: relationship to outcome of therapy in patients with advanced breast cancer. , 1986, Cancer research.
[50] E B Cox,et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.
[51] A. C. Carter,et al. Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response , 1985, Cancer.
[52] W. McGuire,et al. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] G. Greene,et al. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells , 1984, Nature.
[54] C. Nolan,et al. Monoclonal antibodies to human estrogen receptor. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[55] E. J. Gregory,et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. , 1977, Cancer research.
[56] M. DeLaGarza,et al. Evaluation of estrogen receptor assays in human breast cancer tissue. , 1977 .